Captrust Financial Advisors Acquires 1,581 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Captrust Financial Advisors grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 32.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,414 shares of the biopharmaceutical company’s stock after acquiring an additional 1,581 shares during the quarter. Captrust Financial Advisors’ holdings in Alnylam Pharmaceuticals were worth $1,509,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Jennison Associates LLC bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth about $61,160,000. Strategic Financial Concepts LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $41,529,000. Truist Financial Corp grew its holdings in shares of Alnylam Pharmaceuticals by 136.6% during the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company’s stock worth $1,035,000 after buying an additional 2,539 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock worth $67,464,000 after buying an additional 8,462 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Alnylam Pharmaceuticals by 13.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock worth $4,687,000 after buying an additional 2,285 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on ALNY shares. UBS Group increased their price objective on Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Bank of America increased their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a report on Friday, March 21st. HC Wainwright reiterated a “buy” rating and set a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. Royal Bank of Canada increased their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a report on Friday, March 21st. Finally, Citigroup raised their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $319.17.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the completion of the sale, the executive vice president now directly owns 12,881 shares in the company, valued at $3,240,344.36. The trade was a 10.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 1,213 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at $20,802,989.42. This trade represents a 1.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 7,392 shares of company stock worth $1,875,627. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $266.86 on Wednesday. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 12 month low of $144.73 and a 12 month high of $304.39. The stock has a 50 day moving average of $251.33 and a 200-day moving average of $253.69. The company has a market capitalization of $34.80 billion, a P/E ratio of -122.98 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The firm had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. During the same period in the prior year, the company earned ($0.16) EPS. The company’s revenue for the quarter was up 20.2% compared to the same quarter last year. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.